Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Keytruda 50 mg/vial lyophilized powder for injection Images

Generic Name: pembrolizumab

This medication has been identified as Keytruda 50 mg/vial lyophilized powder for injection. It is supplied by Merck.

Keytruda is used in the treatment of Endometrial Cancer; Cervical Cancer; Breast Cancer; Colorectal Cancer; Merkel Cell Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). There is positive evidence of human fetal risk during pregnancy. Keytruda 50 mg/vial lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).

Images

Keytruda (Pembrolizumab [ pem-broe-liz-ue-mab ])-medicine-50 mg/vial lyophilized powder for injection

Keytruda
Generic Name: pembrolizumab [ pem-broe-liz-ue-mab ]
Imprint: medicine
Strength: 50 mg/vial lyophilized powder for injection
Color: N/A
Size: N/A
Shape: N/A
Availability: Prescription only
Drug Class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Pregnancy Category: D - Positive evidence of risk
CSA Schedule: Not a controlled drug
Labeler / Supplier: N/A
National Drug Code (NDC): 00006-3029 (Discontinued)
Inactive Ingredients:
Latest News
Related Drugs